Tuberculosis infects roughly a quarter of the world’s population, yet only about 10.8 million people develop active disease each year. The gap between those two numbers is enormous, and it exists because TB faces a gauntlet of biological bottlenecks, from how hard it is to transmit to how effectively the human immune system walls it off, to the slow-growing nature of the bacterium itself. Each of these barriers dramatically reduces the number of infections that ever become illness.
TB Is Surprisingly Hard to Catch
Compared to viruses like measles or influenza, the bacterium that causes tuberculosis requires prolonged, close-quarters exposure to spread. Research tracking close contacts of infectious TB patients found that the risk of new infection didn’t meaningfully increase until people had shared indoor air for roughly 250 hours. Below that threshold, infection rates among contacts looked no different from the background rate in the general population. Above it, each additional 250 hours of exposure raised the infection rate by about 8 percentage points.
That 250-hour figure puts TB transmission in perspective. You generally need to live with someone, work alongside them daily, or share a confined space for weeks before the odds shift meaningfully in favor of catching it. Brief encounters on a bus or in a waiting room carry very low risk. This is one of the biggest reasons TB doesn’t spread the way a cold or flu does: most human contact simply isn’t long or close enough.
The Immune System’s Containment Strategy
Even when someone does inhale enough bacteria to become infected, the immune system has a remarkably effective containment plan. Within weeks of infection, the body builds structures called granulomas at the site where the bacteria landed in the lungs. These are tight clusters of immune cells, primarily a type of white blood cell called macrophages, surrounded by a ring of other immune cells. The granuloma essentially walls the bacteria off, trapping them in a small pocket of tissue where they can’t spread or cause symptoms.
This containment works so well that about 90% of people with healthy immune systems who become infected will never develop active TB disease. The bacteria sit dormant inside these granulomas, sometimes for decades, held in check by constant immune surveillance. Only about 5% of infected people develop active disease within the first two years, and another 5% do so at some later point in their lives. For the vast majority, latent infection is where the story ends.
A Bacterium That Grows at a Crawl
The TB bacterium itself is unusually slow. While a common gut bacterium like E. coli divides every 20 minutes, Mycobacterium tuberculosis takes about 17 hours to produce a single new cell. Under the stressful conditions inside the human body, that pace slows even further. This glacial replication rate has several consequences that limit the disease’s spread.
Slow growth means the bacterial population stays small for a long time after initial infection, giving the immune system a wider window to detect and contain it. It also means the disease develops gradually in the people who do get sick, with weeks or months passing between infection and the onset of coughing that could spread bacteria to others. And paradoxically, this slowness may actually be a survival strategy for the bacterium. By keeping a low profile and maintaining a tiny population, it avoids triggering the kind of overwhelming immune response that would either kill it outright or kill the host. TB plays a long game, and that long game inherently limits how fast it can spread through a population.
Ventilation, Sunlight, and Living Conditions
TB thrives in specific environmental conditions and is vulnerable in others. The bacterium can survive for months on dry surfaces and persist in dark, poorly ventilated spaces for over 74 days. But ultraviolet light from sunlight is an effective disinfectant, and good airflow disperses the tiny droplets that carry the bacteria, reducing the concentration anyone breathes in.
This is why TB has historically been a disease of crowding and poverty. Packed tenement housing, underground workplaces, and poorly ventilated rooms create ideal transmission conditions. The dramatic decline in TB across industrialized nations during the 19th and early 20th centuries, well before antibiotics existed, was driven largely by improvements in housing, sanitation, nutrition, and public health infrastructure. Better-fed people mount stronger immune responses. Less crowded housing means fewer hours of close contact. More windows and better ventilation mean fewer viable bacteria floating in the air. These factors collectively pushed TB rates down long before anyone understood the biology.
The BCG Vaccine’s Partial Shield
Most of the world’s population receives the BCG vaccine in childhood, and while it’s far from perfect, it adds another layer of protection. The vaccine is 70 to 80% effective at preventing the most severe and deadly forms of TB, particularly TB meningitis in children. Its protection against the common pulmonary form that affects adults is considerably weaker and varies widely by region, which is why TB still circulates even in heavily vaccinated populations. Still, by preventing many of the most dangerous childhood cases, BCG reduces the overall burden and blunts some of the disease’s worst outcomes.
Treatment That Breaks the Chain
When active TB does develop, modern treatment programs are highly effective at curing the disease and stopping transmission. The standard approach involves months of combination antibiotics, often administered under direct observation to ensure patients complete the full course. Programs using this model have achieved treatment success rates of about 82%, compared to roughly 72% without structured support. Each person successfully treated is one fewer source of ongoing transmission, which compounds over time to reduce the number of new infections in a community.
Treatment of latent infection adds another layer. People identified as carrying dormant TB bacteria can take preventive medication that dramatically lowers their chance of ever developing active disease. This is especially important for people at higher risk of progression, such as those with weakened immune systems. In a person with a healthy immune system, the lifetime risk of progressing from latent infection to active disease is about 10%. Conditions that suppress immune function, like HIV, raise that risk substantially, which is why targeted screening and preventive treatment in high-risk groups remains a cornerstone of TB control.
Why It All Adds Up
No single factor explains why TB isn’t more common. Instead, it’s the cumulative effect of multiple barriers stacking on top of each other. Transmission requires prolonged close contact, so most exposures don’t lead to infection. The immune system contains the bacteria in 9 out of 10 infected people, so most infections don’t lead to disease. The bacterium replicates slowly, giving the body time to respond and limiting how quickly sick individuals become contagious. Sunlight and ventilation reduce environmental persistence. Vaccination blunts the worst outcomes in children. And treatment programs cure most active cases before they can spark long chains of transmission.
Each of these filters removes a large fraction of potential cases. Multiply them together and you get the reality we see today: a pathogen that has infected billions of people over human history but produces active disease in a relatively small fraction of them in any given year. TB is common by any reasonable standard, with nearly 11 million new cases and 1.25 million deaths annually. But given how many people carry the bacterium, the question of why it isn’t even more common has a clear answer: biology, immunity, and public health each take a massive bite out of its potential.